NICE指南:疑似癌症的识别和转诊 (2021年更新)[NG12]

2021-12-17 英国国家卫生与临床优化研究所 NICE官网

本指南涵盖识别可能由癌症引起的症状的儿童、年轻人和成人。它概述了初级保健中的适当调查,以及选择参考专家意见的人员。它旨在帮助人们了解如果出现可能表明癌症的症状会发生什么。

中文标题:

NICE指南:疑似癌症的识别和转诊 (2021年更新)[NG12]

英文标题:

Suspected cancer: recognition and referral [NG12]

发布日期:

2021-12-17

简要介绍:

本指南涵盖识别可能由癌症引起的症状的儿童、年轻人和成人。它概述了初级保健中的适当调查,以及选择参考专家意见的人员。它旨在帮助人们了解如果出现可能表明癌症的症状会发生什么。

2021年12 月,NICE审查了有关前列腺特异性抗原检测的固定阈值和年龄调整阈值的证据,并更新了关于疑似前列腺癌转诊的建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=NICE指南:疑似癌症的识别和转诊 (2021年更新)[NG12].pdf)] GetToolGuiderByIdResponse(projectId=1, id=dd5761c002296646, title=NICE指南:疑似癌症的识别和转诊 (2021年更新)[NG12], enTitle=Suspected cancer: recognition and referral [NG12], guiderFrom=NICE官网, authorId=0, author=, summary=本指南涵盖识别可能由癌症引起的症状的儿童、年轻人和成人。它概述了初级保健中的适当调查,以及选择参考专家意见的人员。它旨在帮助人们了解如果出现可能表明癌症的症状会发生什么。, cover=https://img.medsci.cn/20211220/1639975712491_5579292.jpg, journalId=0, articlesId=null, associationId=85, associationName=英国国家卫生与临床优化研究所, associationIntro=英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence)是NHS的组织,设在伦敦和曼彻斯特。NICE成立于1999年4月1日,目标是确保每个英格兰和威尔士人平等享有NHS医疗的机会。NICE制定指南,设定质量标准,管理国家数据库,为NHS、当地权威部门和其他组织提供指南。, copyright=0, guiderPublishedTime=Fri Dec 17 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #0e0e0e;">本指南涵盖识别可能由癌症引起的症状的儿童、年轻人和成人。</span><span style="color: #0e0e0e;">它概述了初级保健中的适当调查,以及选择参考专家意见的人员。</span><span style="color: #0e0e0e;">它旨在帮助人们了解如果出现可能表明癌症的症状会发生什么。</span></p> <p><span style="color: #0e0e0e;">2021<span>年12 月,NICE审查了有关前列腺特异性抗原检测的固定阈值和年龄调整阈值的证据,并更新了</span><span>关于疑似前列腺癌转诊</span><span>的建议。</span></span></p>, tagList=[TagDto(tagId=516, tagName=癌症)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=516, guiderKeyword=癌症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1890, appHits=50, showAppHits=0, pcHits=265, showPcHits=1840, likes=0, shares=9, comments=5, approvalStatus=1, publishedTime=Mon Dec 20 12:35:14 CST 2021, publishedTimeString=2021-12-17, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Dec 20 12:47:18 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 21:48:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=NICE指南:疑似癌症的识别和转诊 (2021年更新)[NG12].pdf)])
NICE指南:疑似癌症的识别和转诊 (2021年更新)[NG12].pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1082918, encodeId=36ef108291859, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 22 07:02:47 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082480, encodeId=e58f108248077, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c22d6415434, createdName=ms6000001183280030, createdTime=Tue Dec 21 09:48:08 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082315, encodeId=b92810823159d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Dec 21 07:02:14 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-22 微探

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1082918, encodeId=36ef108291859, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 22 07:02:47 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082480, encodeId=e58f108248077, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c22d6415434, createdName=ms6000001183280030, createdTime=Tue Dec 21 09:48:08 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082315, encodeId=b92810823159d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Dec 21 07:02:14 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-21 ms6000001183280030

    学习一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1082918, encodeId=36ef108291859, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 22 07:02:47 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082480, encodeId=e58f108248077, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c22d6415434, createdName=ms6000001183280030, createdTime=Tue Dec 21 09:48:08 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082315, encodeId=b92810823159d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Dec 21 07:02:14 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-21 微探

    学习学习

    0

拓展阅读

2014年ASCO 美国成人癌症幸存者疲劳的筛查和管理指南

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2014-04-14

2014 ASE/EACI专家共识:多峰性成像技术评估成人患者癌症治疗期间及之后

美国超声心动图学会(ASE,American Society of Echocardiography) · 2014-07-12

2014 COSA立场声明:癌症患者补充和替代疗法的应用

澳大利亚临床肿瘤学会(COSA,Clinical Oncology Society of Australia) · 2014-09-22

2014 ASCO官方声明:一期试验在 研究和治疗中的重要作用

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2014-12-15

2015 ISTH指南:癌症相关的弥散性血管内凝血的管理

国际血栓与止血学会(ISTH,International Society on Thrombosis and Haemostasis) · 2015-01-05

2014 ASCO 癌症患者静脉血栓栓塞防治指南(更新版)

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2015-01-20